drugset / Trial / NCT07178431

MB-CART2019.1 in Refractory Multiple Sclerosis

NCT07178431

Phase 1/2 Recruiting 26 enrolled Miltenyi Biomedicine GmbH
NaSingle-groupOpen-labelTreatment

Summary

The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.

Timeline

Start
2026-04-01
Primary completion
2030-08-16
Completion
2030-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject MB-CART2019.1 Cell therapy

Indications